Novartis Expects Further Profit, Sales Growth Despite Competition Threat
The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...
Novartis Expects Further Profit, Sales Growth Despite Competition Threat — 2nd Update
Novartis said Friday that it expects core operating profit--one of its preferred metrics, which strips out exceptional items--for 2025 to grow in the high-single-digit to low-double-digit range and ...